Literature DB >> 18606222

Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin.

Y L Lo1, C T Ho, F L Tsai.   

Abstract

Cancer-cell resistance to chemotherapy limits the efficacy of cancer treatment. The primary mechanisms of multidrug resistance (MDR) are "pump" and "non-pump" resistance. We evaluated the effects and mechanisms of glycocholic acid (GC), a bile acid, on inhibiting pump and non-pump resistance, and increasing the chemosensitivity of epirubicin in human colon adenocarcinoma Caco-2 cells and rat intestine. GC increased the cytotoxicity of epirubicin, significantly increased the intracellular accumulation of epirubicin in Caco-2 cells and the absorption of epirubicin in rat small intestine, and intensified epirubicin-induced apoptosis. GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3. This suggests that GC- and epirubicin-induced apoptosis was mediated through the mitochondrial pathway. We conclude that simultaneous suppression of pump and non-pump resistance dramatically increased the chemosensitivity of epirubicin. A combination of anticancer drugs with GC can control MDR via a mechanism that involves modulating P-gp and MRPs as well as regulating apoptosis-related pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606222     DOI: 10.1016/j.ejps.2008.06.003

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  13 in total

1.  Cell death signaling and anticancer therapy.

Authors:  Lorenzo Galluzzi; Ilio Vitale; Erika Vacchelli; Guido Kroemer
Journal:  Front Oncol       Date:  2011-05-03       Impact factor: 6.244

2.  Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.

Authors:  Yu-Li Lo; Yu Liu
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

3.  Evaluation of epirubicin in thermogelling and bioadhesive liquid and solid suppository formulations for rectal administration.

Authors:  Yu-Li Lo; Yijun Lin; Hong-Ru Lin
Journal:  Int J Mol Sci       Date:  2013-12-31       Impact factor: 5.923

4.  Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.

Authors:  Guixia Ling; Tianhong Zhang; Peng Zhang; Jin Sun; Zhonggui He
Journal:  Int J Nanomedicine       Date:  2016-08-23

5.  Cationic PEGylated liposomes incorporating an antimicrobial peptide tilapia hepcidin 2-3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells.

Authors:  Vivian Juang; Hsin-Pin Lee; Anya Maan-Yuh Lin; Yu-Li Lo
Journal:  Int J Nanomedicine       Date:  2016-11-15

Review 6.  Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles.

Authors:  Nebojša Pavlović; Svetlana Goločorbin-Kon; Maja Ðanić; Bojan Stanimirov; Hani Al-Salami; Karmen Stankov; Momir Mikov
Journal:  Front Pharmacol       Date:  2018-11-08       Impact factor: 5.810

7.  A potential daidzein derivative enhances cytotoxicity of epirubicin on human colon adenocarcinoma Caco-2 cells.

Authors:  Yu-Li Lo
Journal:  Int J Mol Sci       Date:  2012-12-21       Impact factor: 5.923

8.  Effects of antibiotic antitumor drugs on nucleotide levels in cultured tumor cells: an exploratory method to distinguish the mechanisms of antitumor drug action based on targeted metabolomics.

Authors:  Fang Wang; Xi Liu; Cuichai Liu; Zheng Liu; Lixin Sun
Journal:  Acta Pharm Sin B       Date:  2015-04-08       Impact factor: 11.413

9.  Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma.

Authors:  Yung-Kuo Lee; Tsung-Hsien Lin; Chuan-Fa Chang; Yu-Li Lo
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

10.  Bile Acids Increase Doxorubicin Sensitivity in ABCC1-expressing Tumour Cells.

Authors:  Simon Chewchuk; Tyler Boorman; Derek Edwardson; Amadeo M Parissenti
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.